AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00152763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Description: Cognitive behavior therapy tailored to psychological adaptation to an ICD, included 8 telephone counselling sessions, plus psycho-educational booklet and a therapist manual.
Study NCT02510105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventilation ( with an ICU conventional ventilator)
Study NCT02155517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evaluation of propofol effect
Description: The study will make in two stages:~STAGE I: All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI device, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes.
Study NCT02155517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evaluation of propofol effect
Description: STAGE II: 72 hours after stage I . All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI devices, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes.
Study NCT02270359 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OCT
Description: Optical coherence tomography (OCT): Intracoronary imaging for amount and type of plaque as well as plaque rupture, ulceration, dissection and/or thrombosis.
Study NCT00152763 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Cardiac Care (UCC)
Description: Usual cardiac care (UCC) was defined as whatever the respective ICD treatment sites routinely offer their patients. All patients received standard educational materials explaining their heart disease and the ICD device. Follow-up appointments include device interrogation (i.e., to extract arrhythmia events and ICD therapies) and trouble-shooting at 6-months intervals, cardiac care as necessary, and nonsystematic supportive reassurance delivered informally in the clinic. Each centre also had access to a cardiac rehabilitation program and psychiatric consultation as needed.
Study NCT02500212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENVARSUS®
Study NCT02500212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADVAGRAF®
Study NCT02270359 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: CMR
Description: Cardiac magnetic resonance imaging (CMR): MRI of the heart to identify areas of infarction (damage) and/or edema (smelling)
Study NCT02270359 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: contrast agent, Gadolinium
Description: Gadolinium contrast will be administered during CMR
Study NCT00439166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxycycline
Description: capsule, 100 mg, b.i.d., daily for 1 year
Study NCT02622763 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tolerogenic Dendritic Cells
Description: Intralesional administration
Study NCT04627532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07304814
Description: Participants will receive PF-07304814
Study NCT04627532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will recieve placebo
Study NCT02111746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Participants will receive 266mg of liposomal bupivicaine (equivalent of one 1.3% 20ml vial of EXPAREL®) diluted in 60ml of preservative-free normal (0.9%) sterile saline for a total volume of 80mL. Drug will be administered at the end of the procedure just prior to wound closure.
Study NCT02111746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine hydrochloride
Description: Participants will receive 125mg of bupivacaine hydrochloride (equivalent of one 0.25% 50ml or five 0.25% 10ml vials ) diluted in 30ml of preservative-free normal (0.9%) sterile saline for a total volume of 80mL. Drug will be administered at the end of the procedure just prior to wound closure.
Study NCT02111746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patient Controlled Analgesia (PCA)
Description: Patients will have access to the standard Patient Controlled Analgesia (PCA) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10 minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs. Patients will receive PCA until the third postoperative day
Study NCT02111746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient Controlled Analgesia (PCA)
Description: Patients will have access to the standard Patient Controlled Analgesia (PCA) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10 minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs. Patients will receive PCA until the third postoperative day
Study NCT01909323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maltitol 85% / FOS15%
Study NCT01909323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maltitol alone
Study NCT01909323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maltitol 68% / FOS 32%
Study NCT01909323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maltitol 50% / FOS 50%
Study NCT01909323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FOS alone
Study NCT01909323 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00199797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin was administered at 85 mg/m2 on day 2 of every 2 week regimen.
Study NCT00199797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: The dose of 5-FU was 400 mg/m2 IV bolus followed by continuous IV infusion at 600 mg/m2 over 22 hours on day 2 and day 3 of every 2 week regimen.
Study NCT00199797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin was administered at a dose of 200mg/m2 on day 2 and day 3 of every 2 week regimen.
Study NCT00199797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: huA33
Description: huA33 was administered intravenously over a period of 30 minutes once a week at a dose of 10 mg/m2.
Study NCT01685489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, PSK®
Study NCT01685489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel, Placebo
Study NCT02027597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attack of the S. Mutans
Description: A research assistant led groups of students through the Attack of the S. Mutans exhibit. All participants played all the games and viewed all the graphical content of the exhibit.
Study NCT02027597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up
Description: This group experienced the Attack of the S. Mutans! exhibit and 3 doses of follow-up booster content at a web site.
Study NCT02027597 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SnowWorld
Description: SnowWorld is a 3D first-person-shooter game developed by Firsthand Technology. In SnowWorld, the player shoots snowballs at penguins, polar bears, and other features of a frozen landscape. The game is designed to help burn victims cope with pain, and has no oral health messages.
Study NCT03376971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo lung biopsy
Study NCT03376971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00465803 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Travoprost 0.004%/timolol 0.5% ophthalmic solution
Description: One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months using the Dosing Aid
Study NCT00465803 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Travoprost ophthalmic solution, 0.004%
Description: One drop in the study eye(s) once daily at 8 PM for twelve months using the Dosing Aid
Study NCT00465803 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Timolol maleate ophthalmic solution, 0.5%
Description: One drop in the study eye(s) once daily at 8 AM or twelve months using the Dosing Aid
Study NCT03086928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lava ultimate
Description: resin nano ceramic material
Study NCT03086928 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E.max cad
Description: Lithium disilicate glass ceramic
Study NCT02370589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Base Dose EBOV GP Vaccine
Study NCT02370589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2x Base Dose EBOV GP Vaccine
Study NCT02370589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4x Base Dose EBOV GP Vaccine
Study NCT02370589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 8x Base Dose EBOV GP Vaccine
Study NCT02370589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02370589 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02370589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M Adjuvant
Study NCT01684098 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tc 99m EC20
Study NCT03134846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab-IRDye800CW
Description: Pre-operatively administration of Cetuximab-IRDye800CW for intra operative margin assessment using a fluorescent antibody-based optical tracer
Study NCT01752881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (split virion, inactivated)
Description: AdimFlu-S, Inactivated Influenza Vaccine Trivalent Types A and B (Split) Formulation 2012-2013~Dosage: 0.5mL/per syringe~Administration route: Intramuscular Injection, once
Study NCT01752881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdimFlu-S
Study NCT02078895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: Peri-Ureteral and Intradetrusor Injection of Botulinum Toxin Type A
Study NCT04306159 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcostal TAP
Description: Subcostal transversus abdominis plane block
Study NCT04306159 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified RSB
Description: Rectus Sheath Block under the guidance of surgical incision
Study NCT04306159 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: General anesthesia
Description: Traditional general anesthesia management
Study NCT03895606 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: This study is an observational study collecting perioperative data. There is no intervention regarding this study.
Study NCT00029536 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Progesterone Lozenges
Description: 200mg Progesterone Lozenges
Study NCT00029536 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo Lozenges
Description: Matched Placebo Lozenges
Study NCT02170090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2
Study NCT02170090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 25mg/m2
Study NCT02170090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1250mg/m2
Study NCT01730534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: Oral dose (od)
Study NCT01730534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Oral dose (od)
Study NCT02990585 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Back school
Study NCT04311749 — intervention group
Intervention type: GENETIC
Intervention: Expanded panel cell free DNA testing (non-invasive prenatal testing)
Description: Maternal blood sampling
Study NCT04311749 — intervention group
Intervention type: GENETIC
Intervention: Placental biopsy
Description: Post-delivery placental sampling
Study NCT00439166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Description: capsule, 300mg, o.d., daily for 11 months (administration starts in 2nd month of trial)
Study NCT00439166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matched to doxycycline
Description: Doxycycline-matched - blue capsule, b.i.d.,daily for 12 months
Study NCT00439166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to doxycycline
Description: Doxycycline-matched - blue capsule, b.i.d.,daily for 12 months
Study NCT00439166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matched to Rifampin
Description: Rifampin-matched - red capsule, o.d., daily for 11 months starting at month 2.
Study NCT00439166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to Rifampin
Description: Rifampin-matched - red capsule, o.d., daily for 11 months starting at month 2.
Study NCT04953013 — intervention group
Intervention type: DRUG
Intervention: sodium bicarbonate
Description: Drug exposure
Study NCT00816387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fallopian tube sperm perfusion
Description: Patients are treated with fallopian tube sperm perfusion
Study NCT00816387 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine insemination using standard catheter
Description: Patients are treated with standard intrauterine insemination
Study NCT02999711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500
Description: REGN3500 dose
Study NCT02999711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study NCT00144872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine will be given as chewable dispersible tablets with dosing strengths of 2, 5, 25, and 100 milligrams.
Study NCT00512551 — intervention group
Intervention type: PROCEDURE
Intervention: Tumor Biopsies
Description: Biopsies of the cervical tumor performed first before any treatment is given, and the second about 48 hours after radiation treatment has began.
Study NCT00902889 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stimulation
Description: 6 weeks stimulation with GPI (lower caudal two contacts), 4 weeks wash-out, 6 weeks stimulation GPE (upper cranial two contacts)
Study NCT00902889 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stimulation
Description: 6 weeks stimulation with GPE (upper cranial two contacts), 4 weeks wash-out, 6 weeks stimulation with GPI (lower caudal two contacts)
Study NCT04653636 — intervention group
Intervention type: OTHER
Intervention: Arthrographic distension
Description: The treatment consists in one to three shoulder joint capsule arthrographic distension. It consists after local anesthesia, in an injection under pressure of xylocaine 1% and physiological serum in the glenohumeral joint associated with an ampoule of corticosteroids (Betamethasone or Triamcinolone hexacetonide ) at the end of the operation.~* first arthrographic distension is performed under scopic guidance~* second and/or third arthrographic distension are performed under ultrasound guidance
Study NCT04653636 — intervention group
Intervention type: OTHER
Intervention: Immediate joint mobilization
Description: This procedure was associated with intensive (immediate mobilization, recovery of maximum amplitudes by the physiotherapist and on arthro-motor).~Physical treatment aimed at rapid amplitude gain and is started immediately after the arthrographic distension, under the effect of local anesthesia. It is at best continued daily at a rate of 2 to 8 hours per day for one to 2 weeks. Depending on the effect obtained on pain and the daily progression of rehabilitation, arthrographic distension may be repeated once or twice during the mobilization period.
Study NCT03545815 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-mesothelin CAR-T cells
Description: Cells will be infused on day 0.
Study NCT03354637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATI-50002 high dose
Description: Topical solution
Study NCT03354637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATI-50002 low dose
Description: Topical solution
Study NCT03354637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical solution
Study NCT00569803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: belatacept
Description: single dose, 116 days
Study NCT00569803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)
Study NCT01313611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab + bendamustine
Description: Induction phase: rituximab and bendamustine on Day 1, Bendamustine on Day 2, Rituximab on Day 8, Rituximab on Day 15, Rituximab on Day 22, bendamustine on Day 29, Bendamustine on Day 30
Study NCT01324479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Study NCT01993823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G238
Description: Five drops into the ear canal twice daily for 14 days
Study NCT01993823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole
Description: Five drops into the ear canal twice daily for 14 days
Study NCT00599989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00599989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00599989 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Study NCT00599989 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Study NCT00599989 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intracavitary balloon brachytherapy
Study NCT00599989 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: proton beam radiation therapy
Study NCT01965158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldemedine
Description: Naldemedine 0.2 mg tablet taken orally once a day
Study NCT01965158 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet taken orally once a day
Study NCT01305746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-623
Description: High dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
Study NCT01305746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-623
Description: Low dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
Study NCT01305746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-623
Description: High dose given subcutaneously once every 4 weeks until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
Study NCT03975426 — intervention group
Intervention type: PROCEDURE
Intervention: open reduction and internal fixation with fixation by absorbable screws
Description: Group A received conservative therapy involving bed rest with the affected lower extremity positioned with the hip and knee in flexion to ensure minimal tension of the muscles attached to the ASIS avulsion fracture. Group B received open reduction and internal fixation with fixation by absorbable screws.
Study NCT02220296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin 338
Description: Healthy subjects will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).
Study NCT02220296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Healthy subjects will receive a single dose of placebo. Injected subcutaneously (under the skin).
Study NCT02220296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin 338
Description: Subjects with type 1 DM will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).
Study NCT02220296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Subjects with type 1 DM will receive 0.4 U/kg insulin glargine once daily for 4 days. Injected subcutaneously (under the skin).
Study NCT01217489 — intervention group
Intervention type: PROCEDURE
Intervention: Breast scan - Electrical Impedance Mammography
Description: Scanning of the breast on a non-invasive device, using harmless minute electrical currents
Study NCT02546154 — intervention group
Intervention type: DRUG
Intervention: 10% Iron Isomaltoside 1000
Description: Standard clinical practice and following the Monofer® label (SPC)
Study NCT01759069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment with microscope
Study NCT01532817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AlphaCore
Description: A single 90 second stimulation to the vagus nerve on the right side of the neck